Medical Developments International (MVP) Q4 2025 earnings summary

Executive summary

• Achieved positive operating cashflow in the second half of FY25, with a $10.7 million improvement year-over-year.

• Cash balance at 30 June 2025 was $17.8 million.

• Penthrox distribution in France and Switzerland transitioned to new partners, with continued growth in Australian hospitals.

Financial highlights

• Q4 FY25 group revenue was $10.2 million, up $0.7 million year-over-year; full-year revenue reached $39.1 million, up $5.9 million.

• Pain Management revenue for Q4 was $7.4 million, up $1.6 million year-over-year; full-year revenue was $26.2 million, up $4.9 million.

• Respiratory revenue for Q4 was $2.7 million, down $0.9 million year-over-year; full-year revenue was $12.8 million, up $1.0 million.

• Cash used in operating activities for FY25 was $43,000, a significant improvement from $10.8 million used in the prior year.

• Receipts from customers in Q4 were $8.5 million, up $0.1 million year-over-year.

Outlook and guidance

• Underlying EBIT for FY25 is expected to be strongly improved on FY24, mainly due to $8 million in benefits from higher Penthrox prices and operational efficiencies.

• Earnings in the second half of FY25 are expected to be lower than the first half due to phasing and foreign exchange movements.